FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a polypeptide that is capable of specifically binding to human L1CAM, as well as to a conjugate containing it and a pharmaceutical composition. The nucleic acid encoding the above-mentioned polypeptide is also disclosed. The invention also relates to the use of the above-mentioned conjugate as a diagnostic agent in vitro.
EFFECT: invention makes it possible to effectively treat or prevent a tumor disease.
23 cl, 7 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
MONOCLONAL ANTIBODIES AND ONE-CHAIN FRAGMENTS OF CELL-SURFACE PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODIES | 2006 |
|
RU2458073C2 |
PROLACTIN RECEPTOR BINDING PROTEINS AND THEIR USE | 2013 |
|
RU2664463C2 |
ANTIBODIES THAT BIND TO PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) | 2013 |
|
RU2689953C2 |
Authors
Dates
2021-09-06—Published
2015-09-28—Filed